Litronesib

DB11861InvestigationalSmall molecule

Litronesib has been used in trials studying the treatment of Solid Tumors, Ovarian Cancer, Gastric Cancer, Prostate Cancer, and Acute Leukaemia, among others.

Mechanism: Pharmacologically active on Kinesin-like protein KIF11
Curator reviewed
Formula / weight: C₂₃H₃₇N₅O₄S₂ · 511.7 g/mol (avg)
Code names: KF-89617 · LY-2523355

Resolves to

Compound

UNII6611F8KYCVCAS910634-41-2ChEMBLCHEMBL2105661PubChem25167017

Structure

InChIKeyYVAFBXLHPINSIK-QHCPKHFHSA-NSMILESCCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C1=CC=CC=C1

Targets

P52732KIF11

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Litronesib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account